LobbyingVanda Pharmaceuticals lobbying by quarter
Vanda Pharmaceuticals VNDA's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q1 2024; the issues it reports most are Pharmacy.
Vanda PharmaceuticalsVNDA
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q1 2024
- The first quarter a report named it
Lobbying by quarter
No lobbying spend in this period.
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $0 | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$0 · 10 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES10 reports
- SENATE10 reports
Firms it paid
| Firm | ||
|---|---|---|
| Manatos & Manatos | $0 | 10 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Manatos & Manatos | Under $5,000 |
| 04/15for Q1 | Manatos & Manatos | Under $5,000 |
| 01/08for Q4 2025 | Manatos & Manatos | Under $5,000 |
| 25/10/19for Q3 2025 | Manatos & Manatos | Under $5,000 |
| 25/07/16for Q2 2025 | Manatos & Manatos | Under $5,000 |
| 25/04/08for Q1 2025 | Manatos & Manatos | Under $5,000 |
| 25/01/14for Q4 2024 | Manatos & Manatos | Under $5,000 |
| 24/10/15for Q3 2024 | Manatos & Manatos | Under $5,000 |
| 24/07/20for Q2 2024 | Manatos & Manatos | Under $5,000 |
| 24/04/24for Q1 2024 | Manatos & Manatos | Under $5,000 |
| 24/01/24for Q1 2024 | Manatos & Manatos | Under $5,000 |